[Form 4] Centessa Pharmaceuticals plc Insider Trading Activity

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (CNTA) reported an insider transaction by its General Counsel on a Form 4. On 11/17/2025, the officer exercised a share option to buy 6,000 Ordinary Shares at $5.84 per share and, on the same day, sold 6,000 Ordinary Shares at a weighted average price of $27.6392 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2024. Following these transactions, the officer directly owns 105,386 Ordinary Shares and holds 221,559 share options beneficially. Each Ordinary Share may be represented by an American Depositary Share on the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUSSAIN IQBAL J

(Last) (First) (Middle)

C/O CENTESSA PHARMACEUTICALS PLC

3RD FL., 1 ASHLEY RD, ALTRINCHAM

(Street)

CHESHIRE X0 WA14 2DT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	11/17/2025		M		6,000	A	$5.84	111,386	D
Ordinary Shares(1)	11/17/2025		S(2)		6,000	D	$27.6392(3)	105,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$5.84	11/17/2025		M			6,000	(4)	02/19/2031	Ordinary Shares(1)	6,000	$0	221,559	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2024.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.505 to $27.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. 25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

Remarks:

	/s/ Raphael Deferiere, attorney-in-fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Centessa Pharmaceuticals (CNTA) report on this Form 4?

The General Counsel of Centessa Pharmaceuticals plc (CNTA) reported exercising an option to buy 6,000 Ordinary Shares at $5.84 and selling 6,000 Ordinary Shares at a weighted average price of $27.6392 on 11/17/2025.

How many Centessa (CNTA) shares does the reporting person own after the transaction?

After the reported transactions, the General Counsel directly owns 105,386 Ordinary Shares of Centessa Pharmaceuticals plc.

What options or derivative securities remain for the Centessa (CNTA) insider?

The reporting person holds 221,559 share options beneficially, including the option from which 6,000 shares were exercised at $5.84 per share.

Was the Centessa (CNTA) insider sale made under a Rule 10b5-1 trading plan?

Yes. The sale of 6,000 Ordinary Shares at a weighted average price of $27.6392 was effected under a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2024.

What is the vesting schedule of the reported Centessa (CNTA) share option?

For the option reported, 25% of the shares vested and became exercisable on February 19, 2022, and the remaining 75% vest and become exercisable in 36 monthly installments on the first day of each month thereafter.

How are Centessa Pharmaceuticals (CNTA) Ordinary Shares represented in the market?

The filing states that Ordinary Shares may be represented by American Depositary Shares (ADS), with each ADS currently representing one Ordinary Share.

What do the transaction codes M and S mean in this Centessa (CNTA) Form 4?

Code M indicates an option exercise (conversion of a derivative security into underlying shares), while code S indicates an open market or private sale of securities, here covering the 6,000-share sale.